Search
Biogen Inc
BIIBAdd to Watchlist
196.580USD
-2.090-1.05%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
29.02BMarket Cap
21.03P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Biogen Inc is 7.47, ranking 102 out of 157 in the Pharmaceuticals industry. The average price target is 171.00, with a high of 260.00 and a low of 130.00.
Analyst Rating
Based on
38
analysts
Buy
Current Rating
220.747
Target Price
+12.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
33
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Biogen Inc's expected revenue for the next quarter?
Biogen Inc's expected revenue is 2.43B.
What is Biogen Inc's price target?
Analysts forecast that Biogen Inc's price target is USD 171.00, with the highest forecast at USD 260.00 and the lowest forecast at USD 130.00.
How have Biogen IncBIIB's recent earnings per share performed?
The market expectation was USD 2.17, while Biogen IncBIIB's earnings per share (EPS) for the previous quarter was USD -0.33. EPS for the next quarter is expected at USD 3.20.
What is the analyst rating for Biogen Inc?
Based on the ratings of Biogen Inc's stock from 38 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
